Skip to content

Study · Randomized controlled trial · n = 505 · 2016

6 results

Efficacy and safety of liraglutide, a once-daily human glucagon-like peptide-1 analogue, in Latino/Hispanic patients with type 2 diabetes: post hoc analysis of data from four phase III trials.

Davidson JA, Ørsted DD, Campos C

Diabetes, obesity & metabolism28 Apr 2016Cited by 12 (Europe PMC)

PMID26936426 (opens in a new tab)DOI10.1111/dom.12653 (opens in a new tab)PepBankPUB-26936426
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In Latino/Hispanic adults with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than the comparator or placebo at 26 weeks in the LEAD-3 and LEAD-4 studies.

    In plain wordsIn Latino/Hispanic adults with type 2 diabetes, liraglutide 1.2 mg lowered HbA1c more than the comparator or placebo in two trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction in Latino/Hispanic patients, 1.2 mg
    Study

    n = 505

    Comparator
    Comparator or placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.2 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In Latino/Hispanic patients (n = 505; 323 treated with liraglutide) after 26 weeks, mean HbA1c reductions were significantly greater with both liraglutide 1.2 and 1.8 mg versus comparator or placebo in the LEAD-3 and LEAD-4 studies
    1 context sentence
    Summary · context
    Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In Latino/Hispanic adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than the comparator or placebo at 26 weeks in the LEAD-3, LEAD-4 and 1860-LIRA-DPP-4 trials.

    In plain wordsIn Latino/Hispanic adults with type 2 diabetes, liraglutide 1.8 mg lowered HbA1c more than the comparator or placebo in three trials.

    Peptide
    Liraglutide
    Outcome
    DecreaseHbA1c reduction in Latino/Hispanic patients, 1.8 mg
    Study

    n = 505

    Comparator
    Comparator or placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In Latino/Hispanic patients (n = 505; 323 treated with liraglutide) after 26 weeks, mean HbA1c reductions were significantly greater with both liraglutide 1.2 and 1.8 mg versus comparator or placebo in the LEAD-3 and LEAD-4 studies, and with 1.8 mg liraglutide in the 1860-LIRA-DPP-4 trial.
    1 context sentence
    Summary · context
    Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In Latino/Hispanic adults with type 2 diabetes in LEAD-3, both liraglutide doses produced significantly different body weight change than the comparator.

    In plain wordsIn Latino/Hispanic adults with type 2 diabetes in one trial, both liraglutide doses changed body weight differently from the comparator.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBody weight change in Latino/Hispanic patients, LEAD-3
    Study

    n: not reported in source

    Comparator
    Comparator or placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.2 and 1.8 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In LEAD-3 both doses led to significant differences in body weight change among Latino/Hispanic patients versus the comparator.
    1 context sentence
    Summary · context
    Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In Latino/Hispanic adults with type 2 diabetes, the difference in weight change with liraglutide 1.8 mg was significant only in the 1860-LIRA-DPP-4 trial, against sitagliptin.

    In plain wordsIn Latino/Hispanic adults with type 2 diabetes, liraglutide 1.8 mg changed weight differently from sitagliptin in one trial only.

    Peptide
    Liraglutide
    Outcome
    Direction not reportedBody weight change with 1.8 mg versus sitagliptin
    Study

    n: not reported in source

    Comparator
    Sitagliptin
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    1.8 mg · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    With 1.8 mg liraglutide, difference in weight change was significant only in the 1860-LIRA-DPP-4 trial versus sitagliptin.
    1 context sentence
    Summary · context
    Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the HbA1c response to liraglutide was similar in Latino/Hispanic and non-Latino/Hispanic patients.

    In plain wordsIn adults with type 2 diabetes, liraglutide lowered HbA1c about the same in Latino/Hispanic and non-Latino/Hispanic patients.

    Peptide
    Liraglutide
    Outcome
    No significant changeHbA1c response, Latino/Hispanic versus non-Latino/Hispanic
    Study

    n: not reported in source

    Comparator
    Non-Latino/Hispanic patients
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    For both endpoints Latino/Hispanic and non-Latino/Hispanic patients responded to liraglutide similarly.
    1 context sentence
    Summary · context
    Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes, the body weight response to liraglutide was similar in Latino/Hispanic and non-Latino/Hispanic patients.

    In plain wordsIn adults with type 2 diabetes, liraglutide changed body weight about the same in Latino/Hispanic and non-Latino/Hispanic patients.

    Peptide
    Liraglutide
    Outcome
    No significant changeBody weight response, Latino/Hispanic versus non-Latino/Hispanic
    Study

    n: not reported in source

    Comparator
    Non-Latino/Hispanic patients
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    For both endpoints Latino/Hispanic and non-Latino/Hispanic patients responded to liraglutide similarly.
    1 context sentence
    Summary · context
    Analyses were performed on patient-level data from a subset of individuals self-defined as Latino/Hispanic from four phase III studies, the LEAD-3, LEAD-4, LEAD-6 and 1860-LIRA-DPP-4 trials.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 3 completed · 1 stopped early · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT00700817

The Effect of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin on Glycaemic Control in Subjects With Type 2 Diabetes Mellitus

Novo Nordisk A/Sn = 665Jun 2008 to Jun 2010

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Mar 2017
CompletedPhase 3Results postedNCT00518882

Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 467Aug 2007 to Apr 2009

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 8 Mar 2017
CompletedPhase 3NCT00333151

Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk A/Sn = 576May 2006 to Aug 2007

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 25 Jan 2017
TerminatedPhase 3Results postedNCT00294723

To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c

Novo Nordisk A/Sn = 746Feb 2006 to Nov 2008

Diabetes · Diabetes Mellitus, Type 2

Trial pageClinicalTrials.govUpdated 7 Mar 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.